[Monoclonal antibodies for treating autoimmune diseases].
Monoclonal antibodies (mAbs) directed to selected cell surface antigens, cytokines and their receptors, and adhesion molecules have been shown to inhibit autoimmune responses in preclinial animal models. Therapeutic trials using the chimeric or humanized mAbs have already been undergoing in patients with rheumatoid arthritis (RA). Effects of anti-CD4 mAb are controversial, but anti-TNF-alpha mAb reveals encouraging results. Although it is too early to determine the efficacy, mAbs are new hopeful therapeutic strategies for autoimmune diseases.
Takeno
M
M
Department of Immunology, St. Marianna University School of Medicine.
Sakane
T
T
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017209:Apoptosis; D001327:Autoimmune Diseases / Q000628:therapy*; D015704:CD4 Antigens / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D051379:Mice; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D015815:Cell Adhesion Molecules; D014409:Tumor Necrosis Factor-alpha